Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer

Inclusion Criteria:

* Are capable of understanding and complying with the requirements of the study and have signed the informed consent from (ICF).
* Very advanced head and neck cancer aged more than 19.
* Longest distance of the tumor is bigger than 1 cm and capable of Intratumoral injection.
* Baseline ECOG Performance Status 0, 1 or 2.
* Have a life expectancy more than 6 months.

Exclusion Criteria:

* Have no history of prior anticancer treatment.
* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.Subject who have participated in a clinical trial of an treatment vaccine or immunotherapy in an year.
* Have a tumor which is near a main vessel that can be occured embolism after injection or which has hypervascularity.
* Patients currently receiving anticancer immuno-therapies Patients who have received prior treatment with an stem cell therapy.
* Have autoimmune disease (multiple sclerosis, systemic lupus erythromatosis, thyroiditis, psoriasis, inflammatory bowel diseases etc.).
* Have Graft rejection reaction such as GVHD.
* Have immunodeficiency disease.
* Leukocytes\< 3.0 x109/L.
* Absolute neutrophil count \< 1.5x109/L.
* Platelet count \< 100 x 109/L.
* Have known positive test for hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV).
* Alanine Aminotransferase (ALT) \> 2.5xUNL.
* Aspartate Aminotransferase (AST)\> 2.5xUNL.
* Total Bilirubin\> UNL.
* Have blood Creatinine\> UNL.
* Known allergy to IL-12 or the excipient(s) of the study medication including fetal bovine serum.
* Second primary cancer Metastatic brain tumor or meningioma.
* Have a tumor near a main artery.
* Uncontrolled hypertension.
* Uncontrolled diabetes uncontrolled (arrhythmia).
* Heart failure (more than NYHA Functional Class II); unstable coronary artery disease; myocardial infarction within 6 months.
* Child-Pugh Class C hepatic impairment.
* Severe renal impairment (creatinine clearance \< 30 ml/min) or on dialysis.
* Have active infection or history of recurrent infection.
* Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.
* Are considered ineligible by the investigator due to a mental disease or CNS disease.
* Administration of any other tumor therapy, including chemotherapy and radiotherapy within 4 weeks(6 weeks in case of nitrosoureas and mytomycin C) before the beginning of study treatment.
* Patients receiving chronic, systemic treatment with immunosuppressive agent(steroid) or immuno-modulator within 2 weeks prior to screening.
* Have participated in another clinical trial within 30 days prior to dosing.